Aeolian Biotech is reaching for an improved pneumococcal vaccine. Our management team includes senior leaders of the intitial Prevnar team at Wyeth and Pfizer. Our iPCV project, based on issued IP exclusively licensed to Aeolian by our founders, will provide protection against 95% of serotypes causing invasive disease in US adults. We have raised seed funding and are now seeking Series A funds that would support the company to clinical proof of concept data, estimated to be available 24 months after close of the Series A round.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Nebraska
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
iPCV
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
